[Alizapride in a double-blind trial with metoclopramide in nausea and vomiting caused by radiotherapy].
Alizapride, a new antiemetic of the benzotriazole-line, enterally given, has been used in a randomized double blind trial including 40 patients suffering from radiogenic gastro-intestinal syndrome. Compared to metoclopramide, alizapride caused a faster regression of inappetence and of the frequency of daily vomiting. Drug-induced side-effects could not be seen.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D001066:Appetite / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea / Q000188:drug therapy*; D009369:Neoplasms / Q000532:radiotherapy*; D011759:Pyrrolidines / Q000627:therapeutic use*; D014839:Vomiting / Q000188:drug therapy*
D000932:Antiemetics; D011759:Pyrrolidines; D008787:Metoclopramide; C033968:alizapride
Alizaprid im Doppelblind-Versuch mit Metoclopramid bei Ubelkeit und Erbrechen infolge einer Strahlentherapie.